ATR inhibitor promise for advanced solid tumours dimmed by liver toxicity
Gartisertib, an oral inhibitor of ataxia telangiectasia and Rad3-related protein (ATR), for patients with advanced solid tumours is well tolerated at lower doses, according to the results of a phase I study. However, unexpected liver toxicity prevents dose escalation and, in turn, limits the drug’s antitumour activity.
